Shares of DexCom jumped over 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices ...

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...

I wore Dexcom’s over-the-counter blood glucose monitor for a month. Here’s how it compares to Lingo and what it’s like to use ...

Discover Dexcom's Q1 2025 earnings highlights, including 14% revenue growth, expanded type 2 diabetes coverage, and the upcoming launch of the 15-day ...

The company reaffirmed its full-year revenue guidance of $4.6 billion and maintained its adjusted ... outlook also remains around 30%. However, DexCom revised its 2025 adjusted gross profit ...

DexCom's growth trend improved in 1Q25, but competition and shrinking market potential keep upside limited. Find out why DXCM ...

DexCom has a price-to-sales (P/S) ratio of 8.0 vs. a figure of 2.8 for the S&P 500 Additionally, the company’s price-to-free cash flow (P/FCF) ratio is 28.1 compared to 17.6 for S&P 500 And ...

Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Ōura, maker of a health-monitoring smart ring, announced that it will use AI to track and analyze two new metabolic health features: meals and glucose.

Shares of DexCom Inc. DXCM rallied 1.57% to $81.53 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.77% to 5,606.91 and ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care ...